ADMA news

Latest 1 stories · newest Aug 5, 2026

ADMA

ADMA Bio reports Q2 2026 results with 24% revenue growth for ASCENIV

ADMA Bio reported Q2 2026 financial results, showing strong growth in ASCENIV revenue and GAAP net income. The company reiterated FY2026 guidance and announced real-world evidence highlighting clinical improvements in treated patients.

Earnings Aug 5, 2026 sentiment +0.90 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same ADMA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/ADMA/newsSTART FREE